Business Context and Reporting Period
This Form 8-K filing by Apyx Medical Corp (APYX) reports on the results of the Annual Meeting of Stockholders held on August 7, 2025. The filing details the voting outcomes for five proposals submitted to shareholders, including director elections, auditor ratification, executive compensation advisory votes, and a charter amendment.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent 10-K or 10-Q filings for financial statements.
Material Changes and Voting Results
The following proposals were approved by stockholders:
- Proposal 1 (Director Elections): Five directors were elected to serve until the 2026 Annual Meeting. All nominees received significant majority support, with votes cast in favor ranging from approximately 18.8 million to 19.1 million.
- Proposal 2 (Auditor Ratification): Stockholders ratified RSM US LLP as the independent registered public accounting firm for the year ending December 31, 2025. The vote was overwhelmingly in favor (25,930,634 for vs. 25,032 against).
- Proposal 3 (Say-on-Pay): Stockholders approved the non-binding advisory resolution supporting the compensation of named executive officers (18,963,101 for vs. 182,700 against).
- Proposal 4 (Say-on-Frequency): Stockholders approved a one-year frequency for future advisory votes on executive compensation (9,205,086 votes for one year).
- Proposal 5 (Charter Amendment): Stockholders approved an amendment to the Certificate of Incorporation to remove Article EIGHTH and replace it with "intentionally omitted" (19,047,016 for vs. 99,065 against).
Guidance, Outlook, and Risks
This filing contains no management commentary regarding business outlook, financial guidance, or specific risk factors. The document strictly reports the procedural outcomes of the shareholder meeting. For detailed risk factors and strategic outlook, investors should consult the Definitive Proxy Statement on Schedule 14A filed on June 25, 2025.
Key Facts for Investor Verification
- Verify the full biographical details and potential conflicts of interest for the newly elected directors in the Schedule 14A Proxy Statement.
- Confirm the specific implications of removing Article EIGHTH from the Certificate of Incorporation, as the text only states it was replaced with "intentionally omitted."
- Note that the "Say-on-Pay" vote frequency was set to one year, indicating a preference for annual shareholder review of executive compensation.
- Review the Schedule 14A for the detailed breakdown of executive compensation that was approved in Proposal 3.